ArticleJournal of virus eradication2021
Motivations, barriers and experiences of participants in an HIV reservoir trial.
Article in Journal of virus eradication, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- The Importance of Social Engagement in the Development of an HIV Cure: A Systematic Review of Stakeholder Perspectives.AIDS and behavior · 2023Pooled it
- Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause in the United States: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.AIDS research and human retroviruses · 2022Trial
- Anxiety Symptom Ratings Before and During the Interruption of Antiretroviral Therapy as Part of HIV Cure-related Studies.Journal of acquired immune deficiency syndromes (1999) · 2026Observational
- Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials.The lancet. HIV · 2026Article
- Perspectives on Analytical Treatment Interruptions and Prospects of an HIV Cure Amongst People Living with HIV and Healthcare Providers in Singapore.AIDS and behavior · 2026Article
- Participant Perspectives in an HIV Treatment Interruption Study in San Francisco, United States.AIDS research and human retroviruses · 2025Article
- Integrating socio-behavioral, ethics, community, and translational science considerations in HIV cure research.Current opinion in HIV and AIDS · 2025Review
- "Sometimes They Exclude Us because of Our Age-That's Not Right": Perceptions of HIV Cure Research Among Diverse Long-Term Survivors in the United States.AIDS research and human retroviruses · 2025Article
- Lessons Learned in Eliciting Systematic Participant Perspectives in a Combination HIV Cure Research Trial.AIDS research and human retroviruses · 2025Article
- Exploring Stigma and Self-Image: Mixed-Methods Insights from HIV Cure-Related Research Participants Undergoing Analytical Treatment Interruptions.AIDS patient care and STDs · 2025Observational
- Evaluating the psychosocial experiences of participants in HIV cure research before, during, and after analytical treatment interruptions: A longitudinal qualitative study in the United States.Social science & medicine (1982) · 2025Article
- Antiretroviral pause for HIV remission trials: A mixed methods study of people living with HIV in Soweto, South Africa.PLOS global public health · 2025Article
- Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium.The lancet. HIV · 2024Review
- Staging of immuno-virological dynamics during acute HIV infection in a Belgian prospective cohort study.Journal of virus eradication · 2024Article
- Call for justice-informed HIV cure trials with ATIs.The lancet. HIV · 2024Article
- Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States.HIV research & clinical practice · 2024Article
- Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States.HIV research & clinical practice · 2023Article
- A partner protection package for HIV cure-related trials involving analytical treatment interruptions.The Lancet. Infectious diseases · 2023Review
- HIV remission trial investigators' attitudes towards risk and risk mitigation in trials that include treatment interruption.Journal of virus eradication · 2023Article
- Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection.Journal of virus eradication · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe aimed to investigate the motives, barriers and experiences of HIV-STAR study participants. The HIV-STAR study was an analytical HIV treatment interruption trial (ATI) aiming to evaluate the origin of viral rebound, conducted in Ghent, Belgium.
methodsA mixed-method study was performed among 11 participants of the HIV-STAR study. Two self-administered questionnaires with 32 and 23 items, respectively, assessed motives, barriers and experiences of the research participants. In-depth interviews were conducted to further explore and understand topics that had emerged from these surveys.
resultsMotives of ATI study participants were primarily related to the improvement of their own health perspectives and to their contribution to find an HIV cure. Barriers for ATI participation mostly related to practical issues, such as difficulty in planning study visits. Ten out of 11 participants reported a very high overall satisfaction and were willing to participate in another ATI. This satisfaction was predominantly linked to clear communication and guidance. Invasive sampling during the ATI was less of a burden than anticipated by participants. However, most participants underestimated the emotional impact of HIV treatment interruption, which was associated with feelings of uncertainty and loss of control. Risk of HIV transmission because of viral rebound was also mentioned as burdensome during this phase.
conclusionsInvolvement in an ATI was positively evaluated by HIV-STAR participants. Contributing to HIV cure research outweighed the burden of study participation for most participants. The latter aspects were attenuated by mutual decision making and the experience of empathy from the research team. Still, issues regarding privacy and the psychosocial impact of treatment interruption, including sexuality and HIV transmissibility, should be addressed in a better way.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.